Published in Medical Letter on the CDC and FDA, January 14th, 2007
In addition to HPV DNA testing for primary screening, the guidelines also recommend use of the test for "proof of cure" following treatment, as well as for follow-up evaluation of women with inconclusive Pap results. The Digene HPV test, which uses the company's proprietary Hybrid Capture II (hc2) technology, detects the presence of high-risk types of the human papillomavirus (HPV), the cause of cervical cancer, and is clinically validated and both U.S. Food and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.